Replies to post #202168 on Biotech Values

[DewDiligence]

OCRX—The only new info is that ~180 patients (of the required 230) have been enrolled in the STOP-HE trial:

https://www.sec.gov/Archives/edgar/data/1274644/000127464416000121/ocera-form8xk7011.htm

The 180 number is a little low but not far off from the company's prior guidance, so this is not a big deal, IMO.

[DewDiligence]

OCRX is up almost 50% since you inquired about it two weeks ago. I don’t think the rise means anything in particular, just as I was pretty sure the drop to the 1.80s didn’t signify anything of consequence (#msg-123459268).